**Gross Cystic Disease Fluid Protein-15 (GCDFP-15)**

**Concentrated and Prediluted Monoclonal Antibody**

901-113-121817

---

**Catalog Number:** CM 113 A, B  
**Description:** 0.1, 0.5 ml, concentrated  
**Dilution:** 1:50  
**Diluent:** Da Vinci Green  
**Dilution:** N/A

---

**Catalog Number:** PM 113 AA  
**Description:** 6.0 ml, prediluted  
**Dilution:** Ready-to-use  
**Diluent:** N/A

---

**Catalog Number:** IP 113 G10  
**Description:** 10 ml, prediluted  
**Dilution:** Ready-to-use

---

**Intended Use:**

For In Vitro Diagnostic Use

Gross Cystic Disease Fluid Protein-15 (GCDFP-15) [D6] is a mouse monoclonal antibody that is intended for laboratory use in the qualitative identification of GCDFP-15 protein by immunohistochemistry (IHC) in formalin-fixed paraffin-embedded (FFPE) human tissues. The clinical interpretation of any staining or its absence should be complemented by morphological studies using proper controls and should be evaluated within the context of the patient's clinical history and other diagnostic tests by a qualified pathologist.

**Summary and Explanation:**

Gross cystic disease fluid is a pathologic secretion from breast composed of several glycoproteins, including GCDFP-15. It is considered to be a marker of apocrine differentiation. Numerous studies have shown GCDFP-15 (BRST-2) to be a specific marker for breast cancer in formalin-fixed paraffin-embedded tissues and in cytologic preparation (fine needle aspirates). Studies on breast cancer have shown, with respect to specificity and sensitivity, an overall rating of 95% and 74% respectively. Another study was conducted on fine needle aspirates and statistics showed that 56.5% of primary and recurrent or metastatic breast carcinomas were expressed with GCDFP-15. Other types of tissues that express GCDFP-15 are axillary sweat glands and submandibular salivary glands.

**Principle of Procedure:**

Antigen detection in tissues and cells is a multi-step immunohistochemical process. The initial step binds the primary antibody to its specific epitope. After labeling the antigen with a primary antibody, a secondary antibody is added to bind to the primary antibody. An enzyme label is then added to bind to the secondary antibody; this detection of the bound antibody is evidenced by a colorimetric reaction.

**Source:** Mouse monoclonal  
**Species Reactivity:** Human; others not tested  
**Clone:** D6  
**Isotype:** IgG2a  
**Total Protein Concentration:** ~10 mg/ml. Call for lot specific Ig concentration.

**Epitope/Antigen:** Gross Cystic Disease Fluid Protein-15  
**Cellular Localization:** Cytoplasmic  
**Positive Tissue Control:** Breast cancer  
**Known Applications:** Immunohistochemistry (formalin-fixed paraffin-embedded tissues)  
**Supplied As:** Buffer with protein carrier and preservative  
**Storage and Stability:** Store at 2°C to 8°C. Do not use after expiration date printed on vial. If reagents are stored under conditions other than those specified in the package insert, they must be verified by the user. Diluted reagents should be used promptly; any remaining reagent should be stored at 2°C to 8°C.

**Protocol Recommendations (intelliPATH and manual use):**

** Peroxide Block:** Block for 5 minutes with Biocare’s Peroxidased 1.  
** Digestion Method:** Digest with Pepsin enzyme for 5 minutes at 37°C ~or~ 15 minutes at RT.  
** Protein Block (Optional):** Incubate for 5-10 minutes at RT with Biocare’s Background Punisher.  
** Primary Antibody:** Incubate for 30 minutes at RT.

**Technical Note:**

This antibody has been optimized for use with Biocare’s MACH 4 Universal HRP-Polymer Detection and intelliPATH Universal HRP Detection Kit. Use TBS for washing steps.

**Limitations:**

The optimum antibody dilution and protocols for a specific application can vary. These include, but are not limited to fixation, heat-retrieval method, incubation times, tissue section thickness and detection kit used. Due to the superior sensitivity of these unique reagents, the recommended incubation times and titers listed are not applicable to other detection systems, as results may vary. The data sheet recommendations and protocols are based on exclusive use of Biocare products. Ultimately, it is the responsibility of the investigator to determine optimal conditions. The clinical interpretation of any positive or negative staining should be evaluated within the context of clinical presentation, morphology and other histopathological criteria by a qualified pathologist. The clinical interpretation of any positive or negative staining should be complemented by morphological studies using proper positive and negative internal and external controls as well as other diagnostic tests.

**Quality Control:**


**Precautions:**

1. This antibody contains less than 0.1% sodium azide. Concentrations less than 0.1% are not reportable hazardous materials according to U.S. 29 CFR 1910.1200, OSHA Hazard communication and EC Directive 91/155/EC. Sodium azide (NaN₃) used as a preservative is toxic if ingested. Sodium azide may react with lead and copper plumbing to form highly explosive metal azides. Upon disposal, flush with large volumes of water to prevent azide build-up in plumbing. (Center for Disease Control, 1976, National Institute of Occupational Safety and Health, 1976) (6)

2. Specimens, before and after fixation, and all materials exposed to them should be handled as if capable of transmitting infection and disposed of with proper precautions. Never pipette reagents by mouth and avoid contacting the skin and mucous membranes with reagents and specimens. If reagents or specimens come in contact with sensitive areas, wash with copious amounts of water. (7)

3. Microbial contamination of reagents may result in an increase in nonspecific staining.
Precautions Cont’d:
4. Incubation times or temperatures other than those specified may give erroneous results. The user must validate any such change.
5. Do not use reagents after the expiration date printed on the vial.
6. The SDS is available upon request and is located at http://biocare.net.

Troubleshooting:
Follow the antibody specific protocol recommendations according to data sheet provided. If atypical results occur, contact Biocare’s Technical Support at 1-800-542-2002.

References: